NCT04208178
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04208178 |
| Title | Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation (EPIK-B2) |
| Acronym | EPIK-B2 |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Novartis Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | ITA | FRA | ESP | BEL |
CKB BOOST